Drug intelligence / Profile preview

KIN-8194

Development stage: Preclinical
Lead developer: Dana-Farber Cancer Institute
Modality: Small Molecules
Administration: Oral

Overview

KIN-8194 is a highly potent dual **HCK (Hematopoietic Cell Kinase)** and **BTK (Bruton's Tyrosine Kinase)** inhibitor. It has an **IC50** of less than 0.495 nM for HCK and 0.915 nM for BTK. KIN-8194 is being investigated for its potential in treating lymphomas, particularly those with **MYD88 mutations**, including Waldenström Macroglobulinemia and diffuse large B-cell lymphoma. It shows promise in overcoming resistance to BTK inhibitors like ibrutinib.

Targets

BTK (Bruton tyrosine kinase)HCK (Haematopoietic Cell Kinase)

Beyond the preview

Go deeper on KIN-8194.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KIN-8194.

Explore the full profile